Sun Pharmaceutical Industries has announced the following results for the quarter & year ended March 31, 2012:
Standalone Results
For the Quarter ended March 31, 2012 (Un-audited)
The net profit of the company surged by 88.31% to Rs702.00 crore for the quarter ended March 31, 2012 as compared to Rs372.78 crore for the quarter ended March 31, 2011.
Total Income has increased by 60.03% to Rs1388.68 crore for the quarter ended March 31, 2012 from Rs867.72 crore for the quarter ended March 31, 2011.
For the Year ended March 31, 2012 (Audited)
The net profit of the company gained by 39.32% to Rs1927.98 crore for the year ended March 31, 2012 as compared to Rs1383.80 crore for the year ended March 31, 2011.
Total Income has increased by 30.33% to Rs4303.91 crore for the year ended March 31, 2012 from Rs3302.30 crore for the year ended March 31, 2011.
Consolidated Results:
For the Quarter ended March 31, 2012 (Un-audited)
The Group has posted a net profit after tax and minority interest of Rs820.21 crore for the quarter ended March 31, 2012 where as the same was at Rs442.75 crore for the quarter ended March 31, 2011.
Total Income is Rs2548.05 crore for the quarter ended March 31, 2012 where as the same was at Rs1595.08 crore for the quarter ended March 31, 2011.
For the Year ended March 31, 2012 (Audited)
The Group has posted a net profit after tax and minority interest of Rs2587.25 crore for the year ended March 31, 2012 where as the same was at Rs1816.06 crore for the year ended March 31, 2011.
Total Income is Rs8429.69 crore for the year ended March 31, 2012 where as the same was at Rs6085.75 crore for the year ended March 31, 2011.
Taro Pharmaceutical Industries Ltd ( Taro), a pharmaceutical company, incorporated in Israel became a subsidiary of the Company on September 20, 2010 therefore the figures for the current financial year are not comparable with the corresponding figures for the previous financial year.
....more info
Standalone Results
For the Quarter ended March 31, 2012 (Un-audited)
The net profit of the company surged by 88.31% to Rs702.00 crore for the quarter ended March 31, 2012 as compared to Rs372.78 crore for the quarter ended March 31, 2011.
Total Income has increased by 60.03% to Rs1388.68 crore for the quarter ended March 31, 2012 from Rs867.72 crore for the quarter ended March 31, 2011.
For the Year ended March 31, 2012 (Audited)
The net profit of the company gained by 39.32% to Rs1927.98 crore for the year ended March 31, 2012 as compared to Rs1383.80 crore for the year ended March 31, 2011.
Total Income has increased by 30.33% to Rs4303.91 crore for the year ended March 31, 2012 from Rs3302.30 crore for the year ended March 31, 2011.
Consolidated Results:
For the Quarter ended March 31, 2012 (Un-audited)
The Group has posted a net profit after tax and minority interest of Rs820.21 crore for the quarter ended March 31, 2012 where as the same was at Rs442.75 crore for the quarter ended March 31, 2011.
Total Income is Rs2548.05 crore for the quarter ended March 31, 2012 where as the same was at Rs1595.08 crore for the quarter ended March 31, 2011.
For the Year ended March 31, 2012 (Audited)
The Group has posted a net profit after tax and minority interest of Rs2587.25 crore for the year ended March 31, 2012 where as the same was at Rs1816.06 crore for the year ended March 31, 2011.
Total Income is Rs8429.69 crore for the year ended March 31, 2012 where as the same was at Rs6085.75 crore for the year ended March 31, 2011.
Taro Pharmaceutical Industries Ltd ( Taro), a pharmaceutical company, incorporated in Israel became a subsidiary of the Company on September 20, 2010 therefore the figures for the current financial year are not comparable with the corresponding figures for the previous financial year.
....more info